KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to -$87000.0.

  • TherapeuticsMD's Change in Account Payables fell 19560.44% to -$87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $29000.0, marking a year-over-year increase of 10627.71%. This contributed to the annual value of $231000.0 for FY2024, which is 11081.97% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Change in Account Payables is -$87000.0, which was down 19560.44% from $174000.0 recorded in Q2 2025.
  • TherapeuticsMD's 5-year Change in Account Payables high stood at $5.0 million for Q3 2021, and its period low was -$10.8 million during Q1 2021.
  • For the 5-year period, TherapeuticsMD's Change in Account Payables averaged around -$219578.9, with its median value being $4000.0 (2024).
  • As far as peak fluctuations go, TherapeuticsMD's Change in Account Payables plummeted by 94683.54% in 2023, and later soared by 425000.0% in 2025.
  • Quarter analysis of 5 years shows TherapeuticsMD's Change in Account Payables stood at $414000.0 in 2021, then plummeted by 80.92% to $79000.0 in 2022, then tumbled by 946.84% to -$669000.0 in 2023, then skyrocketed by 103.59% to $24000.0 in 2024, then plummeted by 462.5% to -$87000.0 in 2025.
  • Its Change in Account Payables stands at -$87000.0 for Q3 2025, versus $174000.0 for Q2 2025 and -$82000.0 for Q1 2025.